113 related articles for article (PubMed ID: 22166275)
1. Effect of mild hepatic or renal impairment on maternal serum screening biochemical measures.
Ying I; Wyatt PR; Nisenbaum R; Ray JG
J Obstet Gynaecol Can; 2011 Dec; 33(12):1218-1222. PubMed ID: 22166275
[TBL] [Abstract][Full Text] [Related]
2. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum screening in Ontario using the triple marker test.
Summers AM; Farrell SA; Huang T; Meier C; Wyatt PR
J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
[TBL] [Abstract][Full Text] [Related]
4. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
5. Maternal serum triple analyte screening in pregnancy.
Graves JC; Miller KE; Sellers AD
Am Fam Physician; 2002 Mar; 65(5):915-20. PubMed ID: 11898965
[TBL] [Abstract][Full Text] [Related]
6. Maternal serum screening.
Carroll JC
Can Fam Physician; 1994 Oct; 40():1756-64. PubMed ID: 7524838
[TBL] [Abstract][Full Text] [Related]
7. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
8. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
[TBL] [Abstract][Full Text] [Related]
9. Screening of maternal serum for fetal Down's syndrome in the first trimester.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
[TBL] [Abstract][Full Text] [Related]
10. Maternal serum screening for neural tube defects and fetal chromosome abnormalities.
Rose NC; Mennuti MT
West J Med; 1993 Sep; 159(3):312-7. PubMed ID: 7694429
[TBL] [Abstract][Full Text] [Related]
11. Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review.
Hui D; Okun N; Murphy K; Kingdom J; Uleryk E; Shah PS
J Obstet Gynaecol Can; 2012 Feb; 34(2):142-153. PubMed ID: 22340063
[TBL] [Abstract][Full Text] [Related]
12. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
13. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.
Akbas SH; Ozben T; Alper O; Ugur A; Yücel G; Lüleci G
Clin Chem Lab Med; 2001 Jun; 39(6):487-90. PubMed ID: 11506458
[TBL] [Abstract][Full Text] [Related]
14. Participation in maternal serum screening for Down syndrome, neural tube defects, and trisomy 18 following screen-positive results in a previous pregnancy.
Rausch DN; Lambert-Messerlian GM; Canick JA
West J Med; 2000 Sep; 173(3):180-3. PubMed ID: 10986181
[TBL] [Abstract][Full Text] [Related]
15. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
16. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
17. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
18. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
[TBL] [Abstract][Full Text] [Related]
19. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.
Palomaki GE; Neveux LM; Knight GJ; Haddow JE
Prenat Diagn; 2003 Mar; 23(3):243-7. PubMed ID: 12627428
[TBL] [Abstract][Full Text] [Related]
20. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
